Jean-Marc Bellemin - Jan 3, 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Chief Financial Officer
Signature
/s/ Jean Marc-Bellemin
Stock symbol
IOVA
Transactions as of
Jan 3, 2023
Transactions value $
-$64,479
Form type
4
Date filed
1/5/2023, 07:45 PM
Previous filing
Jun 16, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +18.9K +198.34% $0.00 28.4K Jan 3, 2023 Direct F1, F2
transaction IOVA Common Stock Tax liability -$64.5K -10.6K -37.22% $6.11 17.8K Jan 3, 2023 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -18.9K -100% $0.00* 0 Jan 3, 2023 Common stock 18.9K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021.
F2 Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
F3 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
F4 Represents common stock remaining after deducting the common stock withheld for taxes.
F5 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F6 As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023.